Osteosarcoma (OS) is an aggressive primary bone malignancy that metastasizes rapidly.
The standard of care has changed little over the previous four decades, and survival rates …

Abstract Background Tyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib
have demonstrated encouraging activity in prolonging progression‐free survival (PFS) in …

Background Previous studies, both in vitro and in vivo, have established that apatinib has
anti-tumor properties. However, insufficient empirical evidence of the efficacy and safety of …

Objectives The NCCN guidelines recommend that the addition of bevacizumab should be
considered in metastatic breast cancers in some circumstances, but there are no …

Background Osteosarcoma is a relatively rare malignant tumor with a high incidence in
young people. The development of tyrosine kinase inhibitors has brought the treatment of …

Background: Antiangiogenic therapy combined with chemotherapy could improve
pathological complete response (pCR) for breast cancer. Apatinib is an oral tyrosine kinase …

Low-grade myofibroblastic sarcoma (LGMS) is a rare, poorly differentiated, malignant tumor.
The disease mainly occurs in the head and neck and rarely metastasizes at any age …

Background Osteosarcoma commonly develops during childhood and adolescence. Only
one-third of osteosarcoma patients have been clinically detected over the age of 40 years …

Background Sarcoma is a highly heterogeneous malignancy with a poor prognosis.
Although chemotherapy and targeted therapy have improved the prognosis to some extent …

Tumor relapse and pulmonary metastasis, especially unresectable lesions, are the major
cause of poor prognosis of patients with osteosarcoma. Anlotinib, a novel small-molecule …